

INSR(Y1361) Antibody

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP22415a

Product Information

Application	WB, E
Primary Accession	P06213
Reactivity	Human
Host	Rabbit
Clonality	polyclonal
Isotype	Rabbit Ig
Clone Names	R04706NP

Additional Information

Other Names	Insulin receptor, IR, 2.7.10.1, CD220, Insulin receptor subunit alpha, Insulin receptor subunit beta, INSR
Target/Specificity	This INSR(Y1361) antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between amino acids from the human region of human INSR(Y1361).
Dilution	WB~~1:1000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	INSR(Y1361) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Background


Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras- MAPK pathway,

which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin- stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFI). Isoform Short has a higher affinity for IGFI binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:[12138094](#) shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:[16831875](#) shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. In adipocytes, inhibits lipolysis (By similarity).

References


Ebina Y.,et al.Cell 40:747-758(1985).
 Ullrich A.,et al.Nature 313:756-761(1985).
 Chen E.Y.,et al.Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases.
 Seino S.,et al.Diabetes 39:123-128(1990).
 Grimwood J.,et al.Nature 428:529-535(2004).

Images



All lanes: Anti-INSR(Y1361) Antibody at 1:1000 dilution
 Lane 1: 293T whole cell lysate Lane 2: HepG2 whole cell lysate
 Lysates/proteins at 20 µg per lane. Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size: 95 KDa
 Blocking/Dilution buffer: 5% NFDm/TBST.

All lanes: Anti-INSR(Y1361) Antibody at 1:1000 dilution +
 293T whole cell lysate Lysates/proteins at 20 µg per lane.
 Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size: 95 KDa
 Blocking/Dilution buffer: 5% NFDm/TBST.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.